Medtronic spacer
Medtronic
Medtronic
Medtronic Home > Information for Physicians > Pain > Pain Therapies > What is Intrathecal Drug Delivery ?
  Pain Therapies
 

Introduction to Chronic Pain

 

Types of Pain

 

Chronic Back & Leg Pain

 

Complex Regional Pain Syndromes

 

Cancer Pain

 

Diagnosis

 

What is Neurostimulation ?

 

What is Intrathecal Drug Delivery ?

Medtronic
Medtronic

Medtronic
Medtronic

What is Intrathecal Drug Delivery ?

Principles of drug delivery
Many studies have demonstrated the efficacy of opioids, such as morphine, in the management
of pain. Pain-relieving drugs can be delivered via several routes of administration, including:

  • Systemic delivery - typically given first line
  • Intraspinal (epidural and intrathecal) delivery - given when patients experience intolerable side effects on systemic drugs

Pain-relieving drugs can be delivered orally, rectally, transdermally or given as an injection (intravenous, subcutaneous, intramuscular). These forms are called systemic delivery because the pain-relieving drug circulates throughout the patient's entire body



Implanted intrathecal drug
delivery system
Pain-relieving drugs can also be delivered intraspinally. Intraspinal delivery can be given in one of two ways;
into the epidural space or into the intrathecal space. Pain-relieving drugs delivered epidurally also circulate systemically. By contrast, pain-relieving drugs delivered intrathecally circulate only in the cerebropsinal fluid (CSF).
Challenges of delivery of pain-relieving drugs
Several challenges accompany delivery of pain-
relieving drugs, including:
  • Barriers to the site of action
  • Dosing issues
  • Potential adverse events

Barriers to the site of action
One challenge with delivery of pain-relieving drugs is that these drugs are water-soluble.
A collection of anatomical structures exist that slow or prevent water-soluble molecules from entering the brain and nervous system. This natural barrier is called the blood-brain barrier. Systemically delivered pain relieving drugs must cross the blood-brain barrier to reach the site
of action (e.g. morphine must reach the opioid receptors in the dorsal horn). However, because
of their water solubility, these systemically circulating molecules cannot easily pass through the blood-brain barrier. As a result, larger doses of the pain-relieving drugs may be required for efficacy.

Intraspinal pain-relieving drugs (e.g. epidural and Intrathecal morphine) are delivered directly
to the site of pain transmission (thereby bypassing the blood-brain barrier). However, while both epidural and Intrathecal routes transport drugs via CSF circulation, epidurally administered pain-relieving drugs must first cross the dura (the protective outer layer of the spinal cord) before entering the CSF. Therefore, when the epidural route of delivery is used, more time and higher doses are required for the pain-relieving drugs to reach their appropriate receptors in the dorsal horn compared with delivery.

Dosing issues
Dosing issues are of special concern in the systemic delivery of pain-relieving drugs as a result
of the adverse effects associated with these compounds. For example, large doses of systemic opioids may be required to treat severe pain. The larger the dose requirement, the more adverse effects a patient is likely to experience. Therefore, a reduction in pain may be achieved at the cost
of such adverse effects as a reduction in a patient's alertness and mobility, nausea, vomiting, constipation, dizziness and dysphoria.

Due to the substantially lower dose required, intraspinal delivery may offer effective pain relief
with fewer potential adverse effects for patients with chronic intractable pain who are experiencing inadequate pain relief or intolerable side effects on high-dose systemic pain-relieving drugs.
In many cases, the Intrathecal pain-relieving drug dose may be reduced to 1/300th of the oral morphine dose.


Oral to intravenous -3:1
Intravenous to epidural - 10:1
Epidural to intrathecal - 10:1
Oral to intrathecal - 300:1
Typical dose conversions for pain-relieving drug delivery

Potential adverse effects of morphine
Regardless of the route of delivery, pain-relieving drugs can cause adverse effects. However,
most adverse effects can be effectively managed by reducing the amount of drug circulating systemically in the patient's body. As IDD requires a lower dose of pain-relieving drugs than systemic drug delivery, IDD can minimise many of the potential adverse effects of pain-relieving drugs or decrease their severity.

Criteria Systemic delivery Epidural delivery Intrathecal delivery
Method of delivery . Must cross the blood-brain barrier before reaching the site of action

. Must cross the dura before reaching the site of action

. Directly infused into the CSF; bypasses the blood-brain barrier
Potential adverse events

. More potential for adverse events than intraspinal delivery including constipation lightheadedness, dizziness, sedation nausea and vomiting

. Greater potential for adverse effects than intrathecal delivery

. Lowest potential for adverse effects

. Potential adverse effects such as pruntis and urinary retention can usually be effectively managed under a physician's care

Dosage requirement

. Substantially higher dosage required than intraspinal delivery

. Higher dosage required than intrathecal, but lower dosage than systemic delivery

. Lower dosage required
(1/10th epidural, 1/300th oral)

Comparison of delivery routes

Intrathecal drug delivery systems
Intrathecal drug delivery (IDD) delivers small doses of pain-relieving drugs, such as morphine,
via a pump (SynchroMed II/SynchroMed EL/Isomed) that is placed surgically under the skin,
directly into the CSF. This route of administration offers the potential for more potent analgesia
with fewer side effects than systemic routes of administration. Studies have shown that patients treated with intrathecal pain-relieving drugs did not experience many of the undesirable side effects observed with oral/parenteral narcotics. This is due to the fact that intrathecal drug infusion is directed to the spinal cord (the site of action), meaning that smaller doses are required than with oral or intravenous methods.

Intrathecal drug delivery system components

An IDD system consists of two basic components that are placed in the body during a surgical procedure:
  • Pump
  • Catheter

SynchroMed EL Intrathecal
(available with a 10mL or 18mL)

SynchroMed II Intrathecal
drug delivery system

(available with a 20mL or 40mL)

Pump
The pump is a round metal device that stores and automatically releases prescribed amounts of pain medication through the catheter directly into the intrathecal space. The exact dosage,
rate and timing prescribed are entered in the pump using a programmer, an external computer-like device that controls
the pump's memory.
As the pump has a predetremined flow rate, the daily dosage
has to be calculated before the pump is filled with medication. Information about the prescription is stored in the pump's memory.



Isomed drug delivery system

The pump holds a finite amount of medication, which means it needs to be refilled periodically.
This is performed by inserting a needle through the skin and into the pump's reservoir.
Refill intervals are typically every 1-3 months, although this may vary depending on individual prescriptions.Medtronic also have a constant rate pump called Isomed which is mainly used
for chemotherapy.


Catheter
The catheter is a small soft tube. The catheter passer is used to help put the catheter in.
One end of the catheter is connected to the pump and the other is placed into the area
surrounding the spinal cord (intrathecal space).



Fully functioning Intrathecal drug delivery system

Functioning intrathecal drug delivery system

The functioning IDD system sends small, programmed
amounts of pain-relieving drugs from the pump, through
the catheter directly into the CSF in the intrathecal space,
where there is a high concentration of receptors.


Benefits of Intrathecal Drug Delivery

Clinical efficacy of IDD

  • Clinical studies have shown that IDD can provide:
    - good to excellent pain relief in 65-80% of selected
       patients, and improvements in activities of daily living.    [1,2,3]
    - a reduction in side effects observed with oral/parenteral   narcotics e.g. tolerance and addiction. [4,5,6]

- less sedation and constipation than systemic drugs. [7]
- lower doses than those required with oral and intravenous methods e.g. the equivalent of 1/300th   of an oral dosage of morphine can often provide effective pain relief. [8]

  • Patients who are required to change from oral to intrathecal drug administration experience an improvement in long-term pain relief.

Intrathecal drug delivery in CRPS

  • In a randomized, double-blind study [9], bolus intrathecal injections of baclofen and continuous intrathecal baclofen were given to 7 women with CRPS type I and II:
    - 86% of patients receiving bolus intrathecal baclofen achieved complete or partial
       resolution of dystonia of the hands.
    - 50% of patients receiving continuous baclofen regained normal hand function, and 33%   also regained their ability of walk.
  • In a prospective study in 15 patients with chronic intractable pain who received intraspinal morphine [10], 11 patients experienced 'good to excellent' pain relief, and 6 patients were able to return to work.

References
1. Winkelmuller M et al. Journal of Neurosurgery 1996;85:458-67
2. Penn R, Paice J. J Neurosurg 1987;67:182-6
3. Paice J et al. J Pain Symptom Manage 1996;11:71-80
4. Follett K et al. Pain 1992;49:21-25
5. Gilmer-Hill H et al. Surg Neurol 1999; 51:6-11
6. Portenoy RK and Savage SR. J Pain Symptom Manage 1997;14(suppl. 3):S27-35
7. Gianino. Practical Pain Management 1996:127-154
8. Krames ES. J Pain Symptom Manage 1996;11:333-352
9. Van Hilten BJ et al. N Engl J Med 2000;343:625-30
10. Kanoff RB. J Am Osteopath Assoc 1994;94:487-93



back
 

top
 

Privacy Statement Terms of Use Medtronic Footer